Q-omics provides the consensus-scored RPA4 profile across patient tissues and cancer cell-line models. RPA4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPA4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RPA4 RNA expression shows 15,840 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRC, and DLBC as cancer lineages where RPA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPA4 survival associations across molecular data types. RPA4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPA4 RNA expression–survival associations across cancer types. High RPA4 expression shows unfavorable associations in KIRC, KIRP, UCEC, UVM, KICH and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPA4 RNA expression.
This table summarizes RPA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPA4 shows higher tumor expression in KIRC, COAD, HNSC, LIHC, UCEC and BRCA. The KIRC box plot shows higher RPA4 RNA expression in tumor versus normal tissue (log2 FC = +0.183, t-test p < 0.001).
This table shows molecular features associated with RPA4 in patient tissues and cancer cell lines. In patient samples, RPA4 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_SCLC.
